Zobrazeno 1 - 10
of 106
pro vyhledávání: '"D. A. Yardley"'
Autor:
Beverly Moy, Deborah A. Dillon, EP Winer, Sara M. Tolaney, Michele Baltay, William T. Barry, Kit Fuhrman, Chau T. Dang, Elizabeth A. Mittendorf, Romualdo Barroso-Sousa, Wafa Osmani, Ian E. Krop, Y.B. Tan, Paul K. Marcom, D. A. Yardley, H Guo, A. Getz
Publikováno v:
Ann Oncol
Background Previous data suggest that the immune microenvironment plays a critical role in human epidermal growth factor receptor 2 (HER2) -positive breast cancer; however, there is little known about the immune profiles of small HER2-positive tumors
Autor:
Rachel A. Freedman, Sara M. Tolaney, D. A. Yardley, Michalina Janiszewska, Heather A. Parsons, Erica L. Mayer, O Metzger Filho, Michelle Demeo, Ian E. Krop, Laura Spring, Aditya Bardia, CL Arteaga, H Guo, G. Viale, Ta King, EP Winer, Eileen Wrabel, AH Partridge, Adrienne G. Waks, IA Mayer, Kornelia Polyak
Publikováno v:
Cancer Research. 79:P1-15
This abstract was withdrawn by the authors. Citation Format: Metzger Filho O, Janiszewska M, Guo H, Yardley D, Mayer I, Spring L, Arteaga C, Wrabel E, DeMeo M, Freedman R, Tolaney S, Waks A, Bardia A, Parsons H, Partridge A, Mayer E, King T, Polyak K
Autor:
Debu Tripathy, S-A Im, Aditya Bardia, Francisco J. Esteva, M. Campone, S Chia, W Bao, O Kong, Andrew T. Chan, D. A. Yardley, I Diaz-Padilla, H. A. Burris, K Rodriguez Lorenc
Publikováno v:
Cancer Research. 79:P6-18
Background: In Phase III trials, ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + various endocrine therapy (ET) partners has demonstrated significantly prolonged progression-free survival vs placebo (PBO) + ET in patients (pts) with hormone
Autor:
Rebecca G. Bagley, Cynthia X. Ma, Yi He, J. Cortés, Andres Forero-Torres, V Moebus, Linda T. Vahdat, CD Turner, Abdel Halim, Melinda L. Telli, M. Melisko, Peter Schmid, G Wright, Esther Holgado, Alberto J. Montero, L Fehrenbacher, K. L. Blackwell, D. A. Yardley, Rita Nanda
Publikováno v:
Cancer Research. 79:P6-20
Background gpNMB is an internalizable transmembrane protein overexpressed in ˜40% of TNBC, and associated with a worse prognosis. Preclinical data implicates gpNMB in tumor invasion and metastasis. GV is a novel ADC designed to deliver monomethyl au
Autor:
KM Rosenthal, D. A. Yardley, Kevin L Obholz, Frankie A. Holmes, S Hurvitz, Joyce A. O'Shaughnessy, Pegram
Publikováno v:
Cancer Research. 79:P6-17
Treatment (tx) choices for HER2+ early stage breast cancer (EBC) have become increasingly complex. Clinicians and patients must decide 1) which chemotherapy and HER2-targeted agents to use, 2) the sequence of surgery and chemotherapy: either neoadjuv
Autor:
S.L. McCune, Carol O'Hear, G.A. Vidal, Maysa M. Abu-Khalaf, S-A Im, D. A. Yardley, M Gutierrez, X Zhang, Adam Brufsky, S Hurvitz, Peter Schmid, Leisha A. Emens, Valentina Boni, Sherene Loi
Publikováno v:
Cancer Research. 79:OT2-06
Background: Cancer immunotherapy (CIT) has significantly improved overall survival across multiple tumor types, but only subsets of patients experience durable response with single-agent CIT. Combinations of CIT with targeted therapy or chemotherapy
Autor:
W Bao, S Chia, DJ Slamon, Gabriel N. Hortobagyi, S-A Im, O Kong, Francisco J. Esteva, S Hurvitz, Debu Tripathy, D. A. Yardley, Andrew T. Chan, I Diaz-Padilla, K Rodriguez Lorenc
Publikováno v:
Cancer Research. 79:P6-18
Background: In three separate Phase III randomized, placebo-controlled trials, ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + various endocrine therapy (ET) partners prolonged progression-free survival (PFS) vs placebo (PBO) + ET in patien
Autor:
Francisco J. Esteva, Andrew T. Chan, O Kong, Paul Wheatley-Price, Arnd Nusch, Y-S Yap, DJ Slamon, H. A. Burris, K Rodriguez Lorenc, D. A. Yardley, A Gaur, I Diaz-Padilla, Thomas Bachelot, Gabe S. Sonke
Publikováno v:
Cancer Research. 79:P6-18
Background: Patients (pts) with advanced breast cancer (ABC) who present with visceral metastases (mets) have a poorer prognosis vs pts with non-visceral disease. In the Phase III MONALEESA (ML) trials, ribociclib (RIB) + endocrine therapy (ET) prolo
Autor:
Donald A. Richards, Lowell L. Hart, Sara M. Tolaney, M. Miller, D. A. Yardley, Paul Richards, JT Beck, Tania Small, Bhuvaneswari Ramaswamy, Gabriel N. Hortobagyi, Michaela Tsai, Francisco J. Esteva, Sibel Blau, Sami Diab, Joseph A. Sparano, Timothy J. Pluard, Das Purkayastha, Patrick S. Ward, A.M. Favret
Publikováno v:
Cancer Research. 78:P5-21
Background: Endocrine-based therapy is the standard of care for patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC), in whom delaying disease progression is the p
Autor:
Lowell L. Hart, Maureen E. Trudeau, Frankie A. Holmes, Laura Biganzoli, TA Traina, D Markova, Vandana G. Abramson, Iulia Cristina Tudor, Ahmad Awada, Patrick G. Morris, L. Gianni, Ayca Gucalp, Steve Chan, EP Winer, R Stewart, Claudio Zamagni, Ian E. Krop, E Barry, D. A. Yardley, Joyce Steinberg, D Wheatley, M.A. Colleoni, J Tarazi, Laura G. Estévez, Lee S. Schwartzberg
Publikováno v:
Cancer Research. 78:GS4-07
Background: The androgen receptor (AR) is expressed in >75% of hormone receptor (HR)+ tumors. AR signaling has been associated with resistance to endocrine therapy (ET). Aromatase inhibitors (AIs) divert estrogen precursors to androgens; in preclinic